2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
2021
Safety considerations for esophageal dilation by anesthetic type: A systematic review
Lerner MZ, Bourdillon AT, Dai F, Brackett A, Kohli N. Safety considerations for esophageal dilation by anesthetic type: A systematic review. American Journal Of Otolaryngology 2021, 42: 103128. PMID: 34216877, DOI: 10.1016/j.amjoto.2021.103128.Peer-Reviewed Original ResearchConceptsEsophageal dilationOffice-based techniqueSystematic reviewDerSimonian-Laird random-effects modelType of anesthesiaSmall case seriesOffice-based proceduresFull-text studiesUse of stentsRandom-effects modelComprehensive literature searchInverse variance weightingAdverse eventsAnesthetic typeCase seriesIntravenous sedationGeneral anesthesiaHigh morbidityAnesthesia techniquesLocal anesthesiaEmbase databasesExclusion criteriaEquivalent safetyPRISMA guidelinesRare disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply